Demand for Novo Nordisk A/S’s glucagone-like peptide-1 (GLP-1) medicines for diabetes remained strong in the first nine months of the year, leading the Danish company to upgrade its financial forecast for 2022. Sales at constant exchange are now expected to increase by 14% to 17% this year, instead of the earlier predicted rise of 12% to 16%. In its latest financial report, Novo said the outlook takes into account periodic supply constraints at some of its manufacturing sites.
